Schedule 13G ownership disclosure

INMED PHARMACEUTICALS INC

Common Shares · CUSIP: 457637601

Event date: 2024-12-13

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • YA II PN, Ltd.

    Shares: 80,372.00 · Class: 9.99%

  • YA Global Investments II (U.S.), LP

    Shares: 80,372.00 · Class: 9.99%

  • Yorkville Advisors Global, LP

    Shares: 80,372.00 · Class: 9.99%

  • Yorkville Advisors Global II, LLC

    Shares: 80,372.00 · Class: 9.99%

  • YA II GP, LP

    Shares: 80,372.00 · Class: 9.99%

  • YAII GP II, LLC

    Shares: 80,372.00 · Class: 9.99%

  • Mark Angelo

    Shares: 80,372.00 · Class: 9.99%

  • SC-Sigma Global Partners, LP

    Shares: 80,372.00 · Class: 9.99%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-24-129622
Form type
SCHEDULE 13G
Filer
InMed Pharmaceuticals Inc.
CIK
CIK 1728328
Filed
Dec 18, 2024
Reporting period
Dec 13, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub